Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 13/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8262366 | 0.87 | BACE1 (0.42) | PDE4ABACE1PDE4DPDE4BPDE4C | |
| SCHEMBL1656659 | 0.83 | BACE1 (0.65) | BACE1KMT2A | |
| SCHEMBL8262899 | 0.79 | SLC6A2 (0.49) | BACE1 | |
| SCHEMBL8262906 | 0.79 | BACE1 (0.60) | BACE1KMT2A | |
| SCHEMBL3827344 | 0.79 | PDE4A (0.47) | PDE4APDE4DPDE4BPDE4C | |
| SCHEMBL8264233 | 0.75 | BACE1 (0.55) | BACE1KMT2A | |
| SCHEMBL12730424 | 0.75 | BACE1 (0.42) | BACE1 | |
| SCHEMBL8262904 | 0.74 | BACE1 (0.52) | BACE1KMT2A | |
| SCHEMBL7039951 | 0.74 | CYP1A2 (0.51) | PDE4AKMT2A | |
| SCHEMBL7037469 | 0.74 | CYP1A2 (0.51) | PDE4AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807396-B1 | 2-AMINOPYRIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-1807396-B1 | 2-AMINOPYRIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2013-06-26 | — | — | EP | disclosed |
| US-7932275-B2 | Suppressing production of amyloid beta | Merck, Sharp & Dohme Corp. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932275-B2 | Suppressing production of amyloid beta | Merck, Sharp & Dohme Corp. (US) | 2011-04-26 | — | — | US | disclosed |
| US-7932275-B2 | Suppressing production of amyloid beta | Merck, Sharp & Dohme Corp. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-1807396-A4 | 2-AMINOPYRIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO INC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080161363-A1 | 2-Aminopyridine Compounds Useful as Beta-Secretase Inhibitors For the Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LLC | 2008-07-03 | — | — | US | disclosed |
| US-20080161363-A1 | 2-Aminopyridine Compounds Useful as Beta-Secretase Inhibitors For the Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LLC | 2008-07-03 | — | — | US | disclosed |
| US-20080161363-A1 | 2-Aminopyridine Compounds Useful as Beta-Secretase Inhibitors For the Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LLC | 2008-07-03 | — | — | US | disclosed |
| EP-1807396-A1 | 2-AMINOPYRIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Merck & Co., Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006060109-A1 | 2-AMINOPYRIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006060109-A1 | 2-AMINOPYRIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161363-A1 | 2-Aminopyridine Compounds Useful as Beta-Secretase Inhibitors For the Treatment of Alzheimer's Disease | BACE1, BACE2, APP | PDE4A 569/4885BACE1 1/4885PDE4D 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.